A Phase 1 interventional study of PF-02341066 and PF-00299804 in Non Small Cell Lung Cancer, sponsored by Pfizer. Completed at 10 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-10-28.
Sponsored by Pfizer · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing crizotinib in Carcinoma, Non-Small-Cell Lung — 4 open to participants now, 6 under way, 1 of them phase 3. Crizotinib · Carcinoma, Non-Small-Cell Lung.
Among the 23 studies testing crizotinib in Carcinoma, Non-Small-Cell Lung, this one is the 13th largest by enrollment, is one of 3 that started in 2010, is one of 5 in phase 1, and was the 4th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →4 of the 23 studies testing crizotinib in Carcinoma, Non-Small-Cell Lung are open now, in 1 country. Recruiting first, the newest first:
Sun Yat-sen University · Sites in China
Ages 18–75
Hunan Province Tumor Hospital · Sites in China
Ages 18+ · Healthy volunteers
Hunan Province Tumor Hospital · Sites in China
Ages 18+
Hunan Province Tumor Hospital · Sites in China
Ages 18+
By country, each count listing its studies:
Crizotinib: first FDA approval 2011 (XALKORI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 3 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 70 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 80 across the 23 interventional studies. Of the 13 that completed or were terminated, 10 (77%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 23 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer: 15 open now, 26 under way, 5 of them phase 3. Of 123 finished, 70 (57%) have results posted.
Among the 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer, this one is the 71st largest by enrollment of the 136 interventional ones that give a count, is one of 7 that started in 2010, is one of 56 in phase 1, and was the 45th registered.
Pfizer’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 1999.
2 of the studies testing crizotinib in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04322890Hunan Province Tumor HospitalTreatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation | 2026-12-24 |
| NCT06563999Sun Yat-sen UniversityNeoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations. | 2027-11-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 23 studies testing crizotinib in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Pfizer’s 158 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
Lung cancer tumors become resistant to the first generation epidermal growth factor receptor (EGFR) inhibitors erlotinib or gefitinib by changing and increasing the activity of two cell signaling pathways: the cMET pathway and the EGFR pathway. Both resistance mechanisms can occur at the same time, in the same patient and even in the same tumor. This study combines a second generation EGFR inhibitor and a cMET inhibitor to block both these pathways in order to overcome resistance and treat this disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PF-02341066 AND PF-00299804: Patients will be treated with combined cMET inhibitor (PF-02341066) and panHER inhibitor (PF-00299804).
Drug: PF-02341066 · Drug: PF-00299804
PF-00299804 FOLLOWED BY COMBINED PF-02341066 AND PF-00299804: Patients will be treated with single agent panHER inhibitor (PF-00299804) until disease progression and then with the maximum tolerated combined dose of cMET inhibitor (PF-02341066) and panHER inhibitor (PF-00299804).
Drug: PF-02341066 · Drug: PF-00299804
Arm 1: The starting dose will be 200 mg by mouth, twice a day of PF 02341066 in tablet form The dose of each drug in the combination \[PF-02341066 and PF-00299804\] will be escalated or de-escalated until the maximum tolerated combined dose is reached. Patients will then be treated with the maximum tolerated combined dose.
Also known as: cMET inhibitor
Arm 1: The starting dose will be 30 mg by mouth once a day of PF-0029804 in tablet form. The dose of each drug in the combination \[PF-02341066 and PF-00299804\] will be escalated or de-escalated until the maximum tolerated combined dose is reached. Patients will then be treated with the maximum tolerated combined dose.
Also known as: panHER inhibitor
Arm 2: With progressive disease the maximum tolerated combined dose of PF-02341066 (given by mouth twice a day in tablet form) and PF-00299804 (given by mouth once a day in tablet form).
Also known as: cMET inhibitor
Arm 2: The dose of 45 mg by mouth once a day of PF-00299804 in tablet form until progressive disease and then the maximum tolerated combined dose of PF-02341066 (given by mouth twice a day in tablet form) and PF-00299804 (given by mouth once a day in tablet form).
Also known as: panHER inhibitor
Overview of Treatment-emergent All Causalities Adverse Events (AEs) in Escalation Phase
AE was any untoward medical occurrence with study drug/ device in a trial participant. Serious adverse event (SAE) was an AE resulting in death, initial or prolonged inpatient hospitalization, life-threatening experience, persistent or significant disability/incapacity, congenital anomaly. Treatment-emergent AEs were those with initial onset or that worsen in severity after the first dose of study medication. AEs were reported from signing of informed consent until 28 days after the last dose of study medication. SAEs were reported after this time frame if considered to be treatment related. The severity of AEs were graded by the investigator using National Cancer Institute (NCI) Common Terminology Criteria for AEs (CTCAE) v.4.02 and was assessed as Grade 0: no change from normal or reference range; Grade 1: mild; Grade 2: moderate; Grade 3: severe; Grade 4: life-threatening or disabling; Grade 5: death related to AE. However the below table included Grade 3, 4, and 5 AEs.
Time frame: Up to Maximum of treatment duration + 28 days for each participant (could be 295 days)
Overview of Treatment-emergent All Causalities AEs in Expansion Phase
AE was any untoward medical occurrence with study drug/ device in a trial participant. SAE was an AE resulting in death, initial or prolonged inpatient hospitalization, life-threatening experience, persistent or significant disability/incapacity, congenital anomaly. Treatment-emergent AEs were those with initial onset or that worsen in severity after the first dose of study medication. AEs were reported from signing of informed consent until 28 days after the last dose of study medication. SAEs were reported after this time frame if considered to be treatment related. The severity of AEs were graded by the investigator using NCI CTCAE v.4.02 and was assessed as Grade 0: no change from normal or reference range; Grade 1: mild; Grade 2: moderate; Grade 3: severe; Grade 4: life-threatening or disabling; Grade 5: death related to AE. However the below table included Grade 3, 4, and 5 AEs.
Time frame: Up to Maximum of treatment duration + 28 days for each participant (could be 295 days)
Overview of Treatment-emergent, Treatment-related AEs in Escalation Phase
An AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. SAE was an AE resulting in death, initial or prolonged inpatient hospitalization, life-threatening experience, persistent or significant disability/incapacity, congenital anomaly. Treatment-emergent AEs were those with initial onset or that worsen in severity after the first dose of study medication. AEs were reported from signing of informed consent until 28 days after the last dose of study medication. SAEs were reported after this time frame if considered to be treatment related. The severity of AEs were graded by the investigator using NCI CTCAE v.4.02 and was assessed as Grade 0: no change from normal or reference range; Grade 1: mild; Grade 2: moderate; Grade 3: severe; Grade 4: life-threatening or disabling; Grade 5: death related to AE. However the below table included Grade 3, 4, and 5 AEs.
Time frame: Up to Maximum of treatment duration + 28 days for each participant (could be 295 days)
Overview of Treatment-emergent, Treatment-related AEs in Expansion Phase
An AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. SAE was an AE resulting in death, initial or prolonged inpatient hospitalization, life-threatening experience, persistent or significant disability/incapacity, congenital anomaly. Treatment-emergent AEs were those with initial onset or that worsen in severity after the first dose of study medication. AEs were reported from signing of informed consent until 28 days after the last dose of study medication. SAEs were reported after this time frame if considered to be treatment related. The severity of AEs were graded by the investigator using NCI CTCAE v.4.02 and was assessed as Grade 0: no change from normal or reference range; Grade 1: mild; Grade 2: moderate; Grade 3: severe; Grade 4: life-threatening or disabling; Grade 5: death related to AE. However the below table included Grade 3, 4, and 5 AEs.
Time frame: Up to Maximum of treatment duration + 28 days for each participant (could be 295 days)
Number of Participants With Dose Limiting Toxicities (DLTs) in Escalation Phase
DLTs were those AEs which occurred in Cycle 1 of treatment in Dose Escalation Phase which may be attributed to study drug \[combined Crizotinib (PF-02341066) plus Dacomitinib (PF-00299804)\] without a clear alternative explanation and despite the use of adequate/maximal medical intervention as dictated by local institutional clinical practices or the judgment of the investigator. The following events were considered DLTs (using CTCAE version 4.02);1. Grade ≥4 hematologic events. 2. Grade ≥3 non-hematological events (except Grade 3/4 asymptomatic hypophosphatemia and Grade 3/4 hyperuricemia without signs and symptoms of gout). Nausea, vomiting or diarrhea had to have persisted at Grade 3 or 4 despite maximal medical therapy. Grade 3 hypertension will be considered a DLT only if the event is unmanageable by standard approved pharmacologic agents or if the symptomatic sequelae are identified despite appropriate medical intervention.
Time frame: Cycle 1 (4 weeks)
Number of Participants With Stable Disease and Stable Disease Duration in Escalation Phase
If a participant had not achieved an objective response with confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) - 1.1 as determined by the investigators, relative to the response evaluable population, but remained stable for at least 6 weeks after first dose, then the best overall response for such a participant was considered as stable disease.
Time frame: From objective response to date of progression or death due to any cause, whichever occurs first (up to post treatment follow-up as 28-35 days after last dose of study treatment)
Number of Participants With Stable Disease and Stable Disease Duration in Expansion Phase
If a participant had not achieved an objective response with confirmed complete response (CR) or partial response (PR) according to RECIST (1.1) as determined by the investigators, relative to the response evaluable population, but remained stable for at least 6 weeks after first dose, then the best overall response for such a participant was considered as stable disease.
Time frame: From objective response to date of progression or death due to any cause, whichever occurs first (up to post treatment follow-up as 28-35 days after last dose of study treatment)
Number of Participants With Objective Response Rate (ORR) in Escalation Phase
ORR was defined as the percent of participants with CR or PR according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) determined by study physicians, relative to the response evaluable population. Participants were considered non-responders until proven otherwise. Thus, participants who: 1) Did not have CR or PR while on study, or 2) Did not have a post-baseline tumor evaluation, or 3) Received anti-tumor treatment other than the study medication prior to reaching a CR or PR, or 4) Died, in progress, or drop out for any reason prior to reaching a CR or PR, were counted as non-responders in the assessment of ORR. To be assigned a status of PR or CR, changes in tumor measurements in participants with responding tumors were confirmed by repeated tumor assessment that were performed 4 weeks after the criteria for response were first met.
Time frame: From objective response to date of progression or death due to any cause, whichever occurs first (up to post treatment follow-up as 28-35 days after last dose of study treatment)
Number of Participants With ORR in Expansion Phase
ORR was defined as the percent of participants with CR or PR according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) determined by study physicians, relative to the response evaluable population. Participants were considered non-responders until proven otherwise. Thus, participants who: 1) Did not have CR or PR while on study, or 2) Did not have a post-baseline tumor evaluation, or 3) Received anti-tumor treatment other than the study medication prior to reaching a CR or PR, or 4) Died, in progress, or drop out for any reason prior to reaching a CR or PR, were counted as non-responders in the assessment of ORR. To be assigned a status of PR or CR, changes in tumor measurements in participants with responding tumors were confirmed by repeated tumor assessment that were performed 4 weeks after the criteria for response were first met.
Time frame: From objective response to date of progression or death due to any cause, whichever occurs first (up to post treatment follow-up as 28-35 days after last dose of study treatment)
Duration of Response for the Only Participant Shown Partial Response in Expansion Phase
This outcome measure presented the duration of response for one participant in expansion cohort 1 who showed partial response.
Time frame: From objective response to date of progression or death due to any cause, whichever occurs first (up to post treatment follow-up as 28-35 days after last dose of study treatment)
Progression Free Survival (PFS) in Escalation Phase
PFS was defined as the time from the date of the first dose to the date of the first documentation of objective tumor progression according to RECIST 1.1 or death on study due to any cause, whichever occurred first. If tumor progression data included more than 1 date, the first date was used.
Time frame: From randomization to objective tumor progression or death (up to post treatment follow-up as 28-35 days after last dose of study treatment)
Progression Free Survival (PFS) in Expansion Phase
PFS was defined as the time from the date of the first dose to the date of the first documentation of objective tumor progression according to RECIST 1.1 or death on study due to any cause, whichever occurred first. If tumor progression data included more than 1 date, the first date was used.
Time frame: From randomization to objective tumor progression or death (up to post treatment follow-up as 28-35 days after last dose of study treatment)
Expression Analysis of Tumor Biomarkers (HGF, EGFR, and c-Met ) at Baseline Using Immunohistochemistry (IHC) Method
Tumor biomarkers such as HGF, EGFR, and c-Met were analyzed in tumor cells (neoplastic compartment) of tumor specimens from both expansion cohorts 1 and 2 by IHC. The H score was derived by summing the percentages of cells staining at each intensity multiplied by the weighted intensity of staining (0, 1+, 2+, 3+, where 3+ indicates the strongest staining, 2+ indicates medium staining, 1+ indicates weak staining, and 0 indicates no staining). Minimum calculated score of 0 to maximum calculated score of 300, where 0 correspond to no expression and maximum score of 300 indicates the strongest expression. However, the biomarker expression level (higher or lower) was not a predictor of outcome.
Time frame: Baseline
Expression Analysis of Tumor Biomarkers (EGFR, and c-Met) at Baseline Using Fluorescent in Situ Hybridization (FISH) Method
Expression of tumor biomarkers EGFR and cMet at Baseline (using FISH method) are presented in this outcome measure.
Time frame: Baseline
Number of Participants With c-Met, HER2, EGFR Amplification and ALK Rearrangement at Baseline Using FISH Method
Participants showed amplification of c-Met, HER2, and EGFR in the tumor cells and gene rearrangement of ALK are presented in this outcome measure.
Time frame: Baseline
Plasma Concentration of sMet by Study Visits
This outcome measure presented the plasma concentration of sMet at different study visits. s-Met was analyzed using an enzyme-linked immunosorbent assay (ELISA).
Time frame: At screening and Cycle 1 Day 1 (C1D1) (6 hours post dose), and C1D15, C2D1, C2D15 (all predose).
Number of Participants With EGFR Mutation at Baseline
Sample analyses were performed in accordance to Good Laboratory Practice (GLP) guidance and included mutation detection for EGFR gene.
Time frame: Baseline
Number of Participants With KRAS Mutation (GLY12CYS) at Baseline
Sample analyses were performed in accordance to GLP guidance and included mutation detection for KRAS gene.
Time frame: Baseline
Number of Participants With PIK3CA Mutation at Baseline
Sample analyses were performed in accordance to GLP guidance and included mutation detection for PIK3CA gene.
Time frame: Baseline
Number of Participants With ROS1 Gene Translocation at Baseline
Sample analyses were performed in accordance to GLP guidance and included translocation detection (RNA based) for ROS1 gene.
Time frame: Baseline
Plasma Crizotinib and PF-06260182 Pharmacokinetic Parameter in Escalation Phase - Area Under the Plasma Concentration-time Profile From Time Zero to the Last Quantifiable Concentration (AUClast)
At each designated time point, blood samples (3 mL) for pharmacokinetic (PK) analysis of crizotinib and its metabolite, PF 06260182 were collected in appropriately labeled collection tubes containing dipotassium ethylenediamine tetra-acetic acid (K2EDTA). The below analysis table included AUClast for crizotinib and PF-06260182. AUClast was calculated using Linear/Log trapezoidal method.
Time frame: Cycle 1 (C1)/Day 1 (D1), C1D15
Plasma Crizotinib and PF-06260182 Pharmacokinetic Parameter in Escalation Phase - Area Under the Plasma Concentration-time Curve 10 (AUC10)
At each designated time point, blood samples (3 mL) for pharmacokinetic (PK) analysis of crizotinib and its metabolite, PF 06260182 were collected in appropriately labeled collection tubes containing dipotassium ethylenediamine tetra-acetic acid (K2EDTA). AUC10 was calculated using Linear/Log trapezoidal method. The below analysis table included geometric Mean and Geometric Coefficient of Variation of AUC10 for crizotinib and PF-06260182. Arithmetic mean was presented if the n=2.
Time frame: C1D1, C1D15
Plasma Crizotinib and PF-06260182 Pharmacokinetic Parameter in Escalation Phase - Maximum Plasma Concentration (Cmax)
At each designated time point, blood samples (3 mL) for pharmacokinetic (PK) analysis of crizotinib and its metabolite, PF 06260182 were collected in appropriately labeled collection tubes containing dipotassium ethylenediamine tetra-acetic acid (K2EDTA). The below analysis table included Cmax for crizotinib and PF-06260182. Cmax was observed directly from data.
Time frame: C1D1, C1D15
Plasma Crizotinib and PF-06260182 Pharmacokinetic Parameter in Escalation Phase - Time of Last Quantifiable Concentration (Tlast)
At each designated time point, blood samples (3 mL) for pharmacokinetic (PK) analysis of crizotinib and its metabolite, PF 06260182 were collected in appropriately labeled collection tubes containing dipotassium ethylenediamine tetra-acetic acid (K2EDTA). The below analysis table included Tlast for crizotinib and PF-06260182. Tlast was observed directly from data.
Time frame: C1D1, C1D15
Plasma Crizotinib and PF-06260182 Pharmacokinetic Parameter in Escalation Phase -Time to Maximum Plasma Concentration (Tmax)
At each designated time point, blood samples (3 mL) for pharmacokinetic (PK) analysis of crizotinib and its metabolite, PF 06260182 were collected in appropriately labeled collection tubes containing dipotassium ethylenediamine tetra-acetic acid (K2EDTA). The below analysis table included Tmax for crizotinib and PF-06260182. Tmax was observed directly from data as time of first occurrence.
Time frame: C1D1, C1D15
Plasma Dacomitinib and PF-05199265 Pharmacokinetic Parameter in Escalation Phase - AUClast
At each designated time point, blood samples (3 mL) for PK analysis of dacomitinib and its metabolite, PF 05199265 were collected in appropriately labeled collection tubes containing dipotassium ethylenediamine tetra-acetic acid (K2EDTA). The below analysis table included AUClast for dacomitinib and PF-05199265. AUClast was calculated using Linear/Log trapezoidal method.
Time frame: C1D1, C1D15
Plasma Dacomitinib and PF-05199265 Pharmacokinetic Parameter in Escalation Phase - AUC24
At each designated time point, blood samples (3 mL) for PK analysis of dacomitinib and its metabolite, PF 05199265 were collected in appropriately labeled collection tubes containing dipotassium ethylenediamine tetra-acetic acid (K2EDTA). The below analysis table included AUC24 for dacomitinib and PF-05199265. AUC24 was calculated using Linear/Log trapezoidal method.
Time frame: C1D1, C1D15
Plasma Dacomitinib and PF-05199265 Pharmacokinetic Parameter in Escalation Phase - Cmax
At each designated time point, blood samples (3 mL) for PK analysis of dacomitinib and its metabolite, PF 05199265 were collected in appropriately labeled collection tubes containing dipotassium ethylenediamine tetra-acetic acid (K2EDTA). The below analysis table included Cmax for dacomitinib and PF-05199265. Cmax was observed directly from data.
Time frame: C1D1, C1D15
Plasma Dacomitinib and PF-05199265 Pharmacokinetic Parameter in Escalation Phase - Tlast
At each designated time point, blood samples (3 mL) for PK analysis of dacomitinib and its metabolite, PF 05199265 were collected in appropriately labeled collection tubes containing dipotassium ethylenediamine tetra-acetic acid (K2EDTA). The below analysis table included Tlast for dacomitinib and PF-05199265. Tlast was observed directly from data.
Time frame: C1D1, C1D15
Plasma Dacomitinib and PF-05199265 Pharmacokinetic Parameter in Escalation Phase - Tmax
At each designated time point, blood samples (3 mL) for PK analysis of dacomitinib and its metabolite, PF 05199265 were collected in appropriately labeled collection tubes containing dipotassium ethylenediamine tetra-acetic acid (K2EDTA). The below analysis table included Tmax for dacomitinib and PF-05199265. Tmax was observed directly from data as time of first occurrence.
Time frame: C1D1, C1D15
Plasma Crizotinib and PF-06260182 Pharmacokinetic Parameter in Expansion Cohort 1 With or Without Co-administration of Dacomitinib - AUClast
Participants were evaluated for the effect of dacomitinib on steady-state PK of crizotinib. PK of crizotinib alone was evaluated on Day -1 (one day before C1D1 on which the combination treatment of crizotinib and dacomitinib started) after a lead in period of continuous BID dosing of crizotinib for approximately 12 days (±2 days). PK of crizotinib and dacomitinib in combination treatment was evaluated on Day 1 of Cycle 2. Blood samples for crizotinib full PK were to be collected on Day -1 and Day 1 of Cycle 2. The below table included PK data for AUClast. AUClast was calculated using Linear/Log trapezoidal method.
Time frame: Day -1 (crizotinib alone), C2D1 (crizotinib + dacomitinib)
Plasma Crizotinib and PF-06260182 Pharmacokinetic Parameter in Expansion Cohort 1 With or Without Co-administration of Dacomitinib - AUC10
Participants were evaluated for the effect of dacomitinib on steady-state PK of crizotinib. PK of crizotinib alone was evaluated on Day -1 (one day before C1D1 on which the combination treatment of crizotinib and dacomitinib started) after a lead in period of continuous BID dosing of crizotinib for approximately 12 days (±2 days). PK of crizotinib and dacomitinib in combination treatment was evaluated on Day 1 of Cycle 2. Blood samples for crizotinib full PK were to be collected on Day -1 and Day 1 of Cycle 2. The below table included PK data for AUC10. AUC10 was calculated using Linear/Log trapezoidal method.
Time frame: Day -1 (crizotinib alone), C2D1 (crizotinib + dacomitinib)
Plasma Crizotinib and PF-06260182 Pharmacokinetic Parameter in Expansion Cohort 1 With or Without Co-administration of Dacomitinib - Cmin
Participants were evaluated for the effect of dacomitinib on steady-state PK of crizotinib. PK of crizotinib alone was evaluated on Day -1 (one day before C1D1 on which the combination treatment of crizotinib and dacomitinib started) after a lead in period of continuous BID dosing of crizotinib for approximately 12 days (±2 days). PK of crizotinib and dacomitinib in combination treatment was evaluated on Day 1 of Cycle 2. Blood samples for crizotinib full PK were to be collected on Day -1 and Day 1 of Cycle 2. The below table included PK data for Cmin. Cmin was observed directly from data.
Time frame: Day -1 (crizotinib alone), C2D1 (crizotinib + dacomitinib)
Plasma Crizotinib and PF-06260182 Pharmacokinetic Parameter in Expansion Cohort 1 With or Without Co-administration of Dacomitinib - Cmax
Participants were evaluated for the effect of dacomitinib on steady-state PK of crizotinib. PK of crizotinib alone was evaluated on Day -1 (one day before C1D1 on which the combination treatment of crizotinib and dacomitinib started) after a lead in period of continuous BID dosing of crizotinib for approximately 12 days (±2 days). PK of crizotinib and dacomitinib in combination treatment was evaluated on Day 1 of Cycle 2. Blood samples for crizotinib full PK were to be collected on Day -1 and Day 1 of Cycle 2. The below table included PK data for Cmax. Cmax was observed directly from data.
Time frame: Day -1 (crizotinib alone), C2D1 (crizotinib + dacomitinib)
Plasma Crizotinib and PF-06260182 Pharmacokinetic Parameter in Expansion Cohort 1 With or Without Co-administration of Dacomitinib - Tlast
Participants were evaluated for the effect of dacomitinib on steady-state PK of crizotinib. PK of crizotinib alone was evaluated on Day -1 (one day before C1D1 on which the combination treatment of crizotinib and dacomitinib started) after a lead in period of continuous BID dosing of crizotinib for approximately 12 days (±2 days). PK of crizotinib and dacomitinib in combination treatment was evaluated on Day 1 of Cycle 2. Blood samples for crizotinib full PK were to be collected on Day -1 and Day 1 of Cycle 2. The below table included PK data for Tlast. Tlast was observed directly from data.
Time frame: Day -1 (crizotinib alone), C2D1 (crizotinib + dacomitinib)
Plasma Crizotinib and PF-06260182 Pharmacokinetic Parameter in Expansion Cohort 1 With or Without Co-administration of Dacomitinib - Tmax
Participants were evaluated for the effect of dacomitinib on steady-state PK of crizotinib. PK of crizotinib alone was evaluated on Day -1 (one day before C1D1 on which the combination treatment of crizotinib and dacomitinib started) after a lead in period of continuous BID dosing of crizotinib for approximately 12 days (±2 days). PK of crizotinib and dacomitinib in combination treatment was evaluated on Day 1 of Cycle 2. Blood samples for crizotinib full PK were to be collected on Day -1 and Day 1 of Cycle 2. The below table included PK data for Tmax. Tmax was observed directly from data as time of first occurrence.
Time frame: Day -1 (crizotinib alone), C2D1 (crizotinib + dacomitinib)
Plasma Dacomitinib and PF-05199265 Pharmacokinetic Parameter in Expansion Cohort 2 With or Without Co-administration of Dacomitinib - AUClast
PK samples for full PK evaluation of dacomitinib were drawn on Day -1 (one day before C1D1 on which the combination treatment of crizotinib and dacomitinib started) and on C2D1. Dacomitinib and PF-05199265 PK parameter (AUClast) following dacomitinib alone and in combination with crizotinib are summarized in the below table. AUClast was calculated using Linear/Log trapezoidal method.
Time frame: Day -1 (dacomitinib alone), C2D1 (crizotinib + dacomitinib)
Plasma Dacomitinib and PF-05199265 Pharmacokinetic Parameter in Expansion Cohort 2 With or Without Co-administration of Dacomitinib - AUC24
PK samples for full PK evaluation of dacomitinib were drawn on Day -1 (one day before C1D1 on which the combination treatment of crizotinib and dacomitinib started) and on C2D1. Dacomitinib and PF-05199265 PK parameter (AUC24) following dacomitinib alone and in combination with crizotinib are summarized in the below table. AUC24 was calculated using Linear/Log trapezoidal method.
Time frame: Day -1 (dacomitinib alone), C2D1 (crizotinib + dacomitinib)
Plasma Dacomitinib and PF-05199265 Pharmacokinetic Parameter in Expansion Cohort 2 With or Without Co-administration of Dacomitinib - Cmin
PK samples for full PK evaluation of dacomitinib were drawn on Day -1 (one day before C1D1 on which the combination treatment of crizotinib and dacomitinib started) and on C2D1. Dacomitinib and PF-05199265 PK parameter (Cmin) following dacomitinib alone and in combination with crizotinib are summarized in the below table. Cmin was observed directly from data.
Time frame: Day -1 (dacomitinib alone), C2D1 (crizotinib + dacomitinib)
Plasma Dacomitinib and PF-05199265 Pharmacokinetic Parameter in Expansion Cohort 2 With or Without Co-administration of Dacomitinib - Cmax
PK samples for full PK evaluation of dacomitinib were drawn on Day -1 (one day before C1D1 on which the combination treatment of crizotinib and dacomitinib started) and on C2D1. Dacomitinib and PF-05199265 PK parameter (Cmax) following dacomitinib alone and in combination with crizotinib are summarized in the below table. Cmax was observed directly from data.
Time frame: Day -1 (dacomitinib alone), C2D1 (crizotinib + dacomitinib)
Plasma Dacomitinib and PF-05199265 Pharmacokinetic Parameter in Expansion Cohort 2 With or Without Co-administration of Dacomitinib - Tlast
PK samples for full PK evaluation of dacomitinib were drawn on Day -1 (one day before C1D1 on which the combination treatment of crizotinib and dacomitinib started) and on C2D1. Dacomitinib and PF-05199265 PK parameter (Tlast) following dacomitinib alone and in combination with crizotinib are summarized in the below table. Tlast was observed directly from data.
Time frame: Day -1 (dacomitinib alone), C2D1 (crizotinib + dacomitinib)
Plasma Dacomitinib and PF-05199265 Pharmacokinetic Parameter in Expansion Cohort 2 With or Without Co-administration of Dacomitinib - Tmax
PK samples for full PK evaluation of dacomitinib were drawn on Day -1 (one day before C1D1 on which the combination treatment of crizotinib and dacomitinib started) and on C2D1. Dacomitinib and PF-05199265 PK parameter (Tmax) following dacomitinib alone and in combination with crizotinib are summarized in the below table. Tmax was observed directly from data as time of first occurrence.
Time frame: Day -1 (dacomitinib alone), C2D1 (crizotinib + dacomitinib)
This was a Phase 1, multicenter, open-label, non-randomized study of combined oral crizotinib and oral dacomitinib in participants with advanced non-small cell lung cancer (NSCLC). The study consisted of a dose Escalation Phase and an Expansion Phase. The Expansion Phase consisted of Expansion Cohort 1 and 2 which ran concurrently.
| Milestone | Crizotinib 200 mg BID/ Dacomitinib 30 mg QD | Crizotinib 200 mg BID/ Dacomitinib 45 mg QD | Crizotinib 250 mg BID/ Dacomitinib 30 mg QD | Crizotinib 250 mg QD/ Dacomitinib 45 mg QD | Expansion Cohort 1 | Expansion Cohort 2 |
|---|---|---|---|---|---|---|
| Started | 14 | 6 | 7 | 6 | 25 | 12 |
| Treated | 14 | 6 | 7 | 6 | 25 | 12 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 14 | 6 | 7 | 6 | 25 | 12 |
| Withdrew: Participant refused further follow-up | 0 | 0 | 0 | 0 | 5 | 1 |
| Withdrew: Unspecified reasons | 8 | 6 | 7 | 5 | 13 | 10 |
| Withdrew: Death | 6 | 0 | 0 | 1 | 7 | 1 |
AE was any untoward medical occurrence with study drug/ device in a trial participant. Serious adverse event (SAE) was an AE resulting in death, initial or prolonged inpatient hospitalization, life-threatening experience, persistent or significant disability/incapacity, congenital anomaly. Treatment-emergent AEs were those with initial onset or that worsen in severity after the first dose of study medication. AEs were reported from signing of informed consent until 28 days after the last dose of study medication. SAEs were reported after this time frame if considered to be treatment related. The severity of AEs were graded by the investigator using National Cancer Institute (NCI) Common Terminology Criteria for AEs (CTCAE) v.4.02 and was assessed as Grade 0: no change from normal or reference range; Grade 1: mild; Grade 2: moderate; Grade 3: severe; Grade 4: life-threatening or disabling; Grade 5: death related to AE. However the below table included Grade 3, 4, and 5 AEs.
| participants | Crizotinib 200 mg BID/ Dacomitinib 30 mg QD | Crizotinib 200 mg BID/ Dacomitinib 45 mg QD | Crizotinib 250 mg BID/ Dacomitinib 30 mg QD | Crizotinib 250 mg QD/ Dacomitinib 45 mg QD |
|---|---|---|---|---|
| Participants with AEs | 14 | 6 | 7 | 6 |
| Participants with Grade 3 or 4 AEs | 9 | 4 | 5 | 5 |
| Participants with Grade 5 AEs | 3 | 0 | 0 | 1 |
| Participants with SAEs | 6 | 2 | 1 | 4 |
AE was any untoward medical occurrence with study drug/ device in a trial participant. SAE was an AE resulting in death, initial or prolonged inpatient hospitalization, life-threatening experience, persistent or significant disability/incapacity, congenital anomaly. Treatment-emergent AEs were those with initial onset or that worsen in severity after the first dose of study medication. AEs were reported from signing of informed consent until 28 days after the last dose of study medication. SAEs were reported after this time frame if considered to be treatment related. The severity of AEs were graded by the investigator using NCI CTCAE v.4.02 and was assessed as Grade 0: no change from normal or reference range; Grade 1: mild; Grade 2: moderate; Grade 3: severe; Grade 4: life-threatening or disabling; Grade 5: death related to AE. However the below table included Grade 3, 4, and 5 AEs.
| Participants | Expansion Cohort 1 | Expansion Cohort 2 |
|---|---|---|
| Participants with AEs | 22 | 11 |
| Participants with Grade 3 or 4 AEs | 12 | 8 |
| Participants with Grade 5 AEs | 3 | 2 |
| Participants with SAEs | 8 | 8 |
An AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. SAE was an AE resulting in death, initial or prolonged inpatient hospitalization, life-threatening experience, persistent or significant disability/incapacity, congenital anomaly. Treatment-emergent AEs were those with initial onset or that worsen in severity after the first dose of study medication. AEs were reported from signing of informed consent until 28 days after the last dose of study medication. SAEs were reported after this time frame if considered to be treatment related. The severity of AEs were graded by the investigator using NCI CTCAE v.4.02 and was assessed as Grade 0: no change from normal or reference range; Grade 1: mild; Grade 2: moderate; Grade 3: severe; Grade 4: life-threatening or disabling; Grade 5: death related to AE. However the below table included Grade 3, 4, and 5 AEs.
| participants | Crizotinib 200 mg BID/ Dacomitinib 30 mg QD | Crizotinib 200 mg BID/ Dacomitinib 45 mg QD | Crizotinib 250 mg BID/ Dacomitinib 30 mg QD | Crizotinib 250 mg QD/ Dacomitinib 45 mg QD |
|---|---|---|---|---|
| Participants with treatment-related AEs | 14 | 6 | 7 | 6 |
| Participants with treatment-related Grade 3/ 4 AEs | 8 | 3 | 3 | 3 |
| Participants with treatment-related Grade 5 AEs | 0 | 0 | 0 | 0 |
| Participants with treatment-related SAEs | 1 | 2 | 0 | 1 |
An AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. SAE was an AE resulting in death, initial or prolonged inpatient hospitalization, life-threatening experience, persistent or significant disability/incapacity, congenital anomaly. Treatment-emergent AEs were those with initial onset or that worsen in severity after the first dose of study medication. AEs were reported from signing of informed consent until 28 days after the last dose of study medication. SAEs were reported after this time frame if considered to be treatment related. The severity of AEs were graded by the investigator using NCI CTCAE v.4.02 and was assessed as Grade 0: no change from normal or reference range; Grade 1: mild; Grade 2: moderate; Grade 3: severe; Grade 4: life-threatening or disabling; Grade 5: death related to AE. However the below table included Grade 3, 4, and 5 AEs.
| Participants | Expansion Cohort 1 | Expansion Cohort 2 |
|---|---|---|
| Participants with treatment-related AEs | 22 | 11 |
| Participants with treatment-related Grade 3/ 4 AEs | 7 | 6 |
| Participants with treatment-related Grade 5 AEs | 0 | 0 |
| Participants with treatment-related SAEs | 3 | 3 |
DLTs were those AEs which occurred in Cycle 1 of treatment in Dose Escalation Phase which may be attributed to study drug \[combined Crizotinib (PF-02341066) plus Dacomitinib (PF-00299804)\] without a clear alternative explanation and despite the use of adequate/maximal medical intervention as dictated by local institutional clinical practices or the judgment of the investigator. The following events were considered DLTs (using CTCAE version 4.02);1. Grade ≥4 hematologic events. 2. Grade ≥3 non-hematological events (except Grade 3/4 asymptomatic hypophosphatemia and Grade 3/4 hyperuricemia without signs and symptoms of gout). Nausea, vomiting or diarrhea had to have persisted at Grade 3 or 4 despite maximal medical therapy. Grade 3 hypertension will be considered a DLT only if the event is unmanageable by standard approved pharmacologic agents or if the symptomatic sequelae are identified despite appropriate medical intervention.
| Participants | Crizotinib 200 mg BID/ Dacomitinib 30 mg QD | Crizotinib 200 mg BID/ Dacomitinib 45 mg QD | Crizotinib 250 mg BID/ Dacomitinib 30 mg QD | Crizotinib 250 mg QD/ Dacomitinib 45 mg QD |
|---|---|---|---|---|
| Grade 3 Alanine aminotransferase increased | 0 | 1 | 0 | 0 |
| Grade 3 Diarrhoea | 0 | 1 | 0 | 0 |
| Grade 3 Mucosal inflammation | 0 | 0 | 1 | 0 |
If a participant had not achieved an objective response with confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) - 1.1 as determined by the investigators, relative to the response evaluable population, but remained stable for at least 6 weeks after first dose, then the best overall response for such a participant was considered as stable disease.
| Participants | Crizotinib 200 mg BID/ Dacomitinib 30 mg QD | Crizotinib 200 mg BID/ Dacomitinib 45 mg QD | Crizotinib 250 mg BID/ Dacomitinib 30 mg QD | Crizotinib 250 mg QD/ Dacomitinib 45 mg QD |
|---|---|---|---|---|
| Stable Disease | 10 | 3 | 2 | 5 |
| 0- < 3 months | 3 | 2 | 1 | 0 |
| 3- < 6 months | 6 | 1 | 1 | 3 |
| 6- < 9 months | 1 | 0 | 0 | 2 |
If a participant had not achieved an objective response with confirmed complete response (CR) or partial response (PR) according to RECIST (1.1) as determined by the investigators, relative to the response evaluable population, but remained stable for at least 6 weeks after first dose, then the best overall response for such a participant was considered as stable disease.
| Participants | Expansion Cohort 1 | Expansion Cohort 2 |
|---|---|---|
| Stable Disease | 6 | 5 |
| 0- < 3 months | 1 | 0 |
| 3- < 6 months | 4 | 4 |
| 6- < 9 months | 1 | 1 |
ORR was defined as the percent of participants with CR or PR according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) determined by study physicians, relative to the response evaluable population. Participants were considered non-responders until proven otherwise. Thus, participants who: 1) Did not have CR or PR while on study, or 2) Did not have a post-baseline tumor evaluation, or 3) Received anti-tumor treatment other than the study medication prior to reaching a CR or PR, or 4) Died, in progress, or drop out for any reason prior to reaching a CR or PR, were counted as non-responders in the assessment of ORR. To be assigned a status of PR or CR, changes in tumor measurements in participants with responding tumors were confirmed by repeated tumor assessment that were performed 4 weeks after the criteria for response were first met.
| Participants | Crizotinib 200 mg BID/ Dacomitinib 30 mg QD | Crizotinib 200 mg BID/ Dacomitinib 45 mg QD | Crizotinib 250 mg BID/ Dacomitinib 30 mg QD | Crizotinib 250 mg QD/ Dacomitinib 45 mg QD |
|---|---|---|---|---|
| Number of Participants With Objective Response Rate (ORR) in Escalation Phase | 0 (0.0 to 23.2) | 0 (0.0 to 45.9) | 0 (0.0 to 41.0) | 0 (0.0 to 45.9) |
ORR was defined as the percent of participants with CR or PR according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) determined by study physicians, relative to the response evaluable population. Participants were considered non-responders until proven otherwise. Thus, participants who: 1) Did not have CR or PR while on study, or 2) Did not have a post-baseline tumor evaluation, or 3) Received anti-tumor treatment other than the study medication prior to reaching a CR or PR, or 4) Died, in progress, or drop out for any reason prior to reaching a CR or PR, were counted as non-responders in the assessment of ORR. To be assigned a status of PR or CR, changes in tumor measurements in participants with responding tumors were confirmed by repeated tumor assessment that were performed 4 weeks after the criteria for response were first met.
| Participants | Expansion Cohort 1 | Expansion Cohort 2 |
|---|---|---|
| Number of Participants With ORR in Expansion Phase | 1 (0.1 to 22.8) | 0 (0.0 to 26.5) |
This outcome measure presented the duration of response for one participant in expansion cohort 1 who showed partial response.
| Weeks | Expansion Cohort 1 | Expansion Cohort 2 |
|---|---|---|
| Duration of Response for the Only Participant Shown Partial Response in Expansion Phase | 6.29 | — |
PFS was defined as the time from the date of the first dose to the date of the first documentation of objective tumor progression according to RECIST 1.1 or death on study due to any cause, whichever occurred first. If tumor progression data included more than 1 date, the first date was used.
| Months | Crizotinib 200 mg BID/ Dacomitinib 30 mg QD | Crizotinib 200 mg BID/ Dacomitinib 45 mg QD | Crizotinib 250 mg BID/ Dacomitinib 30 mg QD | Crizotinib 250 mg QD/ Dacomitinib 45 mg QD |
|---|---|---|---|---|
| Progression Free Survival (PFS) in Escalation Phase | 3.1 (1.6 to 5.5) | 3.0 (1.5 to 4.4) | 1.7 (1.6 to 4.6) | 4.4 (1.6 to 7.2) |
PFS was defined as the time from the date of the first dose to the date of the first documentation of objective tumor progression according to RECIST 1.1 or death on study due to any cause, whichever occurred first. If tumor progression data included more than 1 date, the first date was used.
| Months | Expansion Cohort 1 | Expansion Cohort 2 |
|---|---|---|
| Progression Free Survival (PFS) in Expansion Phase | 2.1 (1.4 to 4.4) | 2.1 (1.4 to 5.3) |
Tumor biomarkers such as HGF, EGFR, and c-Met were analyzed in tumor cells (neoplastic compartment) of tumor specimens from both expansion cohorts 1 and 2 by IHC. The H score was derived by summing the percentages of cells staining at each intensity multiplied by the weighted intensity of staining (0, 1+, 2+, 3+, where 3+ indicates the strongest staining, 2+ indicates medium staining, 1+ indicates weak staining, and 0 indicates no staining). Minimum calculated score of 0 to maximum calculated score of 300, where 0 correspond to no expression and maximum score of 300 indicates the strongest expression. However, the biomarker expression level (higher or lower) was not a predictor of outcome.
| H-Score | Expansion Cohort 1 | Expansion Cohort 2 |
|---|---|---|
| HGF (N= 19, 11) | 40.0 (0 to 280) | 67.0 (0 to 104) |
| EGFR (N= 14, 8) | 193.2 (2 to 300) | 170.0 (7 to 300) |
| cMet (N= 19, 11) | 125.0 (0 to 300) | 165.0 (20 to 299) |
Expression of tumor biomarkers EGFR and cMet at Baseline (using FISH method) are presented in this outcome measure.
| Ratio | Expansion Cohort 1 | Expansion Cohort 2 |
|---|---|---|
| Ratio of Red to Green of EGFR (N= 11, 11) | 1.580 (0.98 to 3.59) | 1.180 (0.94 to 4.63) |
| Ratio of Green to Orange for cMET (N = 19, 11) | 1.040 (0.43 to 2.12) | 1.000 (0.88 to 1.10) |
Participants showed amplification of c-Met, HER2, and EGFR in the tumor cells and gene rearrangement of ALK are presented in this outcome measure.
| Participants | Expansion Cohort 1 | Expansion Cohort 2 |
|---|---|---|
| c-Met amplification (N= 19, 11) | 1 (0.98 to 3.59) | 0 (0.94 to 4.63) |
| HER2 amplification (N= 19, 7) | 0 | 0 |
| EGFR amplification (N= 11,11) | 2 | 3 |
| ALK rearrangement (N= 19, 11) | 0 | 0 |
This outcome measure presented the plasma concentration of sMet at different study visits. s-Met was analyzed using an enzyme-linked immunosorbent assay (ELISA).
| pg/mL | Expansion Cohort 1 | Expansion Cohort 2 |
|---|---|---|
| Baseline at Screening | 1353411.8 ± 349746.88 | 1557000.0 ± 514352.02 |
| C1D1 | 1519047.6 ± 230995.77 | 1450500.0 ± 553557.13 |
| C1D15 | 1483157.9 ± 243904.64 | 1676666.7 ± 540246.86 |
| C2D1 | 1525666.7 ± 394836.61 | 1540000.0 ± 315515.45 |
| C2D15 | 1564666.7 ± 224367.90 | 1602500.0 ± 126589.89 |
Sample analyses were performed in accordance to Good Laboratory Practice (GLP) guidance and included mutation detection for EGFR gene.
| Participants | Expansion Cohort 1 | Expansion Cohort 2 |
|---|---|---|
| Exon 18 (G719X) | 1 | 1 |
| Exon 19 (Deletion) | 6 | 3 |
| Exon 20 (T790M) | 6 | 3 |
| Exon 20 (T790M/S768I) | 1 | 0 |
| Exon 20 (S768I) | 0 | 1 |
| Exon 21 (L858R) | 6 | 1 |
Sample analyses were performed in accordance to GLP guidance and included mutation detection for KRAS gene.
| Participants | Expansion Cohort 1 | Expansion Cohort 2 |
|---|---|---|
| Number of Participants With KRAS Mutation (GLY12CYS) at Baseline | 1 | 0 |
Sample analyses were performed in accordance to GLP guidance and included mutation detection for PIK3CA gene.
| Participants | Expansion Cohort 1 | Expansion Cohort 2 |
|---|---|---|
| Exon 20 (M1004I) (N= 14, 6) | 1 | 0 |
| Exon 20 (Q1061K) (N= 14, 6) | 1 | 0 |
| Exon 20 (H1047R) (N= 14, 6) | 2 | 0 |
| Exon 9 (E545K) (N= 14, 6) | 1 | 0 |
Sample analyses were performed in accordance to GLP guidance and included translocation detection (RNA based) for ROS1 gene.
| Participants | Expansion Cohort 1 | Expansion Cohort 2 |
|---|---|---|
| Number of Participants With ROS1 Gene Translocation at Baseline | 0 | 0 |
At each designated time point, blood samples (3 mL) for pharmacokinetic (PK) analysis of crizotinib and its metabolite, PF 06260182 were collected in appropriately labeled collection tubes containing dipotassium ethylenediamine tetra-acetic acid (K2EDTA). The below analysis table included AUClast for crizotinib and PF-06260182. AUClast was calculated using Linear/Log trapezoidal method.
| ng•hr/mL | Crizotinib 200 mg BID/ Dacomitinib 30 mg QD | Crizotinib 200 mg BID/ Dacomitinib 45 mg QD | Crizotinib 250 mg BID/ Dacomitinib 30 mg QD | Crizotinib 250 mg QD/ Dacomitinib 45 mg QD |
|---|---|---|---|---|
| Crizotinib C1D1 - single dose (n= 11, 6, 7, 6) | 509.7 ± 62 | 420.8 ± 53 | 506.6 ± 29 | 656.6 ± 65 |
| Crizotinib C1D15 multiple dose (n=8, 3, 6, 5) | 1759 ± 39 | 2464 ± 14 | 1732 ± 35 | 1672 ± 44 |
| PF-06260182 C1D1 - single dose (n= 11, 6, 7, 6) | 121.3 ± 76 | 103.2 ± 74 | 121.6 ± 29 | 220.7 ± 55 |
| PF-06260182 C1D15 - multiple dose (n=8, 3, 6, 5) | 382.3 ± 52 | 593.5 ± 53 | 440.5 ± 37 | 532.0 ± 68 |
At each designated time point, blood samples (3 mL) for pharmacokinetic (PK) analysis of crizotinib and its metabolite, PF 06260182 were collected in appropriately labeled collection tubes containing dipotassium ethylenediamine tetra-acetic acid (K2EDTA). AUC10 was calculated using Linear/Log trapezoidal method. The below analysis table included geometric Mean and Geometric Coefficient of Variation of AUC10 for crizotinib and PF-06260182. Arithmetic mean was presented if the n=2.
| ng•hr/mL | Crizotinib 200 mg BID/ Dacomitinib 30 mg QD | Crizotinib 200 mg BID/ Dacomitinib 45 mg QD | Crizotinib 250 mg BID/ Dacomitinib 30 mg QD | Crizotinib 250 mg QD/ Dacomitinib 45 mg QD |
|---|---|---|---|---|
| Crizotinib C1D1 - single dose (n= 8, 3, 4, 6) | 624.9 ± 57 | 500.8 ± 9 | 559.6 ± 26 | 655.8 ± 65 |
| Crizotinib C1D15 multiple dose (n= 5, 2, 6, 5) | 2000 ± 43 | 2620 ± NA | 1732 ± 35 | 1644 ± 44 |
| PF-06260182 C1D1 - single dose (n= 8, 3, 4, 6) | 162.1 ± 57 | 127.6 ± 32 | 141.5 ± 25 | 228.0 ± 57 |
| PF-06260182 C1D15 - multiple dose (n= 5, 2, 6, 5) | 452.5 ± 48 | 798.0 ± NA | 473.3 ± 39 | 525.5 ± 68 |
At each designated time point, blood samples (3 mL) for pharmacokinetic (PK) analysis of crizotinib and its metabolite, PF 06260182 were collected in appropriately labeled collection tubes containing dipotassium ethylenediamine tetra-acetic acid (K2EDTA). The below analysis table included Cmax for crizotinib and PF-06260182. Cmax was observed directly from data.
| ng/mL | Crizotinib 200 mg BID/ Dacomitinib 30 mg QD | Crizotinib 200 mg BID/ Dacomitinib 45 mg QD | Crizotinib 250 mg BID/ Dacomitinib 30 mg QD | Crizotinib 250 mg QD/ Dacomitinib 45 mg QD |
|---|---|---|---|---|
| Crizotinib C1D1 - single dose (n= 11, 6, 7, 6) | 84.24 ± 58 | 94.13 ± 22 | 90.86 ± 29 | 114.0 ± 61 |
| Crizotinib C1D15 multiple dose (n=8, 3, 6, 5) | 231.5 ± 41 | 329.7 ± 12 | 218.1 ± 33 | 268.9 ± 77 |
| PF-06260182 C1D1 - single dose (n= 11, 6, 7, 6) | 18.50 ± 72 | 22.37 ± 26 | 20.97 ± 29 | 34.33 ± 61 |
| PF-06260182 C1D15 - multiple dose (n=8, 3, 6, 5) | 49.73 ± 50 | 78.45 ± 44 | 57.56 ± 34 | 83.23 ± 91 |
At each designated time point, blood samples (3 mL) for pharmacokinetic (PK) analysis of crizotinib and its metabolite, PF 06260182 were collected in appropriately labeled collection tubes containing dipotassium ethylenediamine tetra-acetic acid (K2EDTA). The below analysis table included Tlast for crizotinib and PF-06260182. Tlast was observed directly from data.
| Hour | Crizotinib 200 mg BID/ Dacomitinib 30 mg QD | Crizotinib 200 mg BID/ Dacomitinib 45 mg QD | Crizotinib 250 mg BID/ Dacomitinib 30 mg QD | Crizotinib 250 mg QD/ Dacomitinib 45 mg QD |
|---|---|---|---|---|
| Crizotinib C1D1 - single dose (n= 11, 6, 7, 6) | 9.92 ± 58 | 9.33 ± 22 | 9.05 ± 29 | 9.75 ± 61 |
| Crizotinib C1D15 multiple dose (n=8, 3, 6, 5) | 9.29 ± 41 | 9.42 ± 25 | 9.05 ± 47 | 10.2 ± 35 |
| PF-06260182 C1D1 - single dose (n= 11, 6, 7, 6) | 9.92 ± 72 | 9.33 ± 26 | 9.05 ± 29 | 9.75 ± 61 |
| PF-06260182 C1D15 - multiple dose (n=8, 3, 6, 5) | 9.29 ± 50 | 9.42 ± 44 | 9.05 ± 34 | 10.2 ± 91 |
At each designated time point, blood samples (3 mL) for pharmacokinetic (PK) analysis of crizotinib and its metabolite, PF 06260182 were collected in appropriately labeled collection tubes containing dipotassium ethylenediamine tetra-acetic acid (K2EDTA). The below analysis table included Tmax for crizotinib and PF-06260182. Tmax was observed directly from data as time of first occurrence.
| Hour | Crizotinib 200 mg BID/ Dacomitinib 30 mg QD | Crizotinib 200 mg BID/ Dacomitinib 45 mg QD | Crizotinib 250 mg BID/ Dacomitinib 30 mg QD | Crizotinib 250 mg QD/ Dacomitinib 45 mg QD |
|---|---|---|---|---|
| Crizotinib C1D1 - single dose (n= 11, 6, 7, 6) | 3.00 ± 58 | 3.53 ± 22 | 3.92 ± 29 | 3.06 ± 61 |
| Crizotinib C1D15 multiple dose (n=8, 3, 6, 5) | 1.68 ± 41 | 6.17 ± 25 | 2.00 ± 47 | 6.00 ± 35 |
| PF-06260182 C1D1 - single dose (n= 11, 6, 7, 6) | 4.07 ± 72 | 4.00 ± 26 | 3.98 ± 29 | 4.99 ± 61 |
| PF-06260182 C1D15 - multiple dose (n=8, 3, 6, 5) | 4.03 ± 50 | 6.17 ± 44 | 4.09 ± 34 | 6.00 ± 91 |
At each designated time point, blood samples (3 mL) for PK analysis of dacomitinib and its metabolite, PF 05199265 were collected in appropriately labeled collection tubes containing dipotassium ethylenediamine tetra-acetic acid (K2EDTA). The below analysis table included AUClast for dacomitinib and PF-05199265. AUClast was calculated using Linear/Log trapezoidal method.
| ng•hr/mL | Crizotinib 200 mg BID/ Dacomitinib 30 mg QD | Crizotinib 200 mg BID/ Dacomitinib 45 mg QD | Crizotinib 250 mg BID/ Dacomitinib 30 mg QD | Crizotinib 250 mg QD/ Dacomitinib 45 mg QD |
|---|---|---|---|---|
| Dacomitinib C1D1 - single dose (n= 10, 6, 7, 5) | 208.3 ± 72 | 132.3 ± 153 | 146.3 ± 86 | 307.7 ± 56 |
| Dacomitinib C1D15 multiple dose (n= 8, 4, 6, 4) | 1339 ± 47 | 2343 ± 70 | 1212 ± 15 | 1775 ± 31 |
| PF-5199265 C1D1 - single dose (n= 8, 6, 6, 6) | 27.68 ± 80 | 7.438 ± 115 | 10.19 ± 190 | 55.00 ± 75 |
| PF-06260182 C1D15 - multiple dose (n= 8, 4, 6, 4) | 51.48 ± 108 | 52.24 ± 78 | 44.97 ± 90 | 161.0 ± 33 |
At each designated time point, blood samples (3 mL) for PK analysis of dacomitinib and its metabolite, PF 05199265 were collected in appropriately labeled collection tubes containing dipotassium ethylenediamine tetra-acetic acid (K2EDTA). The below analysis table included AUC24 for dacomitinib and PF-05199265. AUC24 was calculated using Linear/Log trapezoidal method.
| ng•hr/mL | Crizotinib 200 mg BID/ Dacomitinib 30 mg QD | Crizotinib 200 mg BID/ Dacomitinib 45 mg QD | Crizotinib 250 mg BID/ Dacomitinib 30 mg QD | Crizotinib 250 mg QD/ Dacomitinib 45 mg QD |
|---|---|---|---|---|
| Dacomitinib C1D1 - single dose (n= 8, 3, 5, 5) | 252.7 ± 61 | 347.9 ± 26 | 223.4 ± 23 | 306.6 ± 57 |
| Dacomitinib C1D15 multiple dose (n= 8, 4, 6, 4) | 1336 ± 48 | 2334 ± 69 | 1203 ± 15 | 1745 ± 30 |
| PF-5199265 C1D1 - single dose (n= 9, 3, 5, 6) | 28.57 ± 87 | 14.80 ± 51 | 16.08 ± 169 | 54.72 ± 76 |
| PF-06260182 C1D15 - multiple dose (n= 8, 4, 6, 4) | 51.37 ± 108 | 51.97 ± 78 | 44.72 ± 90 | 158.1 ± 31 |
At each designated time point, blood samples (3 mL) for PK analysis of dacomitinib and its metabolite, PF 05199265 were collected in appropriately labeled collection tubes containing dipotassium ethylenediamine tetra-acetic acid (K2EDTA). The below analysis table included Cmax for dacomitinib and PF-05199265. Cmax was observed directly from data.
| ng/mL | Crizotinib 200 mg BID/ Dacomitinib 30 mg QD | Crizotinib 200 mg BID/ Dacomitinib 45 mg QD | Crizotinib 250 mg BID/ Dacomitinib 30 mg QD | Crizotinib 250 mg QD/ Dacomitinib 45 mg QD |
|---|---|---|---|---|
| Dacomitinib C1D1 - single dose (n= 10, 6, 7, 5) | 15.56 ± 58 | 17.49 ± 23 | 12.40 ± 21 | 18.22 ± 64 |
| Dacomitinib C1D15 multiple dose (n= 8, 4, 6, 4) | 65.00 ± 52 | 122.4 ± 75 | 57.04 ± 13 | 86.81 ± 38 |
| PF-5199265 C1D1 - single dose (n= 10, 6, 6, 7) | 1.894 ± 89 | 0.9888 ± 79 | 0.8833 ± 130 | 3.193 ± 74 |
| PF-06260182 C1D15 - multiple dose (n= 8, 4, 6, 4) | 2.367 ± 115 | 2.649 ± 75 | 2.073 ± 95 | 7.560 ± 34 |
At each designated time point, blood samples (3 mL) for PK analysis of dacomitinib and its metabolite, PF 05199265 were collected in appropriately labeled collection tubes containing dipotassium ethylenediamine tetra-acetic acid (K2EDTA). The below analysis table included Tlast for dacomitinib and PF-05199265. Tlast was observed directly from data.
| Hour | Crizotinib 200 mg BID/ Dacomitinib 30 mg QD | Crizotinib 200 mg BID/ Dacomitinib 45 mg QD | Crizotinib 250 mg BID/ Dacomitinib 30 mg QD | Crizotinib 250 mg QD/ Dacomitinib 45 mg QD |
|---|---|---|---|---|
| Dacomitinib C1D1 - single dose (n= 11, 6, 7, 5) | 24.0 ± 8.00 | 15.9 ± 15.9 | 23.6 ± 24.0 | 24.0 (23.0 to 24.3) |
| Dacomitinib C1D15 multiple dose (n= 8, 4, 6, 4) | 24.00 (23.0 to 24.3) | 23.9 (23.5 to 24.5) | 23.9 (22.9 to 24.8) | 24.4 (24.0 to 25.6) |
| PF-5199265 C1D1 - single dose (n= 8, 6, 6, 6) | 24.0 (8.00 to 24.6) | 15.9 (4.08 to 24.0) | 23.5 (7.55 to 24.1) | 24.1 (23.0 to 24.5) |
| PF-06260182 C1D15 - multiple dose (n= 8, 4, 6, 4) | 24.0 (23.0 to 24.3) | 23.9 (23.5 to 24.5) | 23.9 (22.9 to 24.8) | 24.4 (24.0 to 25.6) |
At each designated time point, blood samples (3 mL) for PK analysis of dacomitinib and its metabolite, PF 05199265 were collected in appropriately labeled collection tubes containing dipotassium ethylenediamine tetra-acetic acid (K2EDTA). The below analysis table included Tmax for dacomitinib and PF-05199265. Tmax was observed directly from data as time of first occurrence.
| Hour | Crizotinib 200 mg BID/ Dacomitinib 30 mg QD | Crizotinib 200 mg BID/ Dacomitinib 45 mg QD | Crizotinib 250 mg BID/ Dacomitinib 30 mg QD | Crizotinib 250 mg QD/ Dacomitinib 45 mg QD |
|---|---|---|---|---|
| Dacomitinib C1D1 - single dose (n= 11, 6, 7, 5) | 5.99 ± 8.00 | 8.03 ± 15.9 | 6.00 ± 24.0 | 6.17 (5.92 to 8.00) |
| Dacomitinib C1D15 multiple dose (n= 8, 4, 6, 4) | 6.00 (0.0 to 23.1) | 5.09 (3.97 to 23.5) | 6.09 (4.15 to 8.13) | 5.00 (4.00 to 6.00) |
| PF-5199265 C1D1 - single dose (n= 8, 6, 6, 6) | 6.95 (3.93 to 24.1) | 4.04 (3.97 to 8.00) | 6.78 (3.98 to 8.05) | 6.08 (3.98 to 24.3) |
| PF-06260182 C1D15 - multiple dose (n= 8, 4, 6, 4) | 6.98 (0.0 to 23.1) | 3.95 (2.00 to 6.17) | 5.92 (0.0 to 23.9) | 2.00 (0.0 to 5.98) |
Participants were evaluated for the effect of dacomitinib on steady-state PK of crizotinib. PK of crizotinib alone was evaluated on Day -1 (one day before C1D1 on which the combination treatment of crizotinib and dacomitinib started) after a lead in period of continuous BID dosing of crizotinib for approximately 12 days (±2 days). PK of crizotinib and dacomitinib in combination treatment was evaluated on Day 1 of Cycle 2. Blood samples for crizotinib full PK were to be collected on Day -1 and Day 1 of Cycle 2. The below table included PK data for AUClast. AUClast was calculated using Linear/Log trapezoidal method.
| ng•hr/mL | Crizotinib Alone (Expansion Cohort 1) | Crizotinib + Dacomitinib (Expansion Cohort 1) |
|---|---|---|
| Crizotinib (n = 16, 13) | 2223 ± 53 | 1365 ± 47 |
| PF-06260182 (n = 16, 13) | 616.3 ± 77 | 356.6 ± 61 |
Participants were evaluated for the effect of dacomitinib on steady-state PK of crizotinib. PK of crizotinib alone was evaluated on Day -1 (one day before C1D1 on which the combination treatment of crizotinib and dacomitinib started) after a lead in period of continuous BID dosing of crizotinib for approximately 12 days (±2 days). PK of crizotinib and dacomitinib in combination treatment was evaluated on Day 1 of Cycle 2. Blood samples for crizotinib full PK were to be collected on Day -1 and Day 1 of Cycle 2. The below table included PK data for AUC10. AUC10 was calculated using Linear/Log trapezoidal method.
| ng•hr/mL | Crizotinib Alone (Expansion Cohort 1) | Crizotinib + Dacomitinib (Expansion Cohort 1) |
|---|---|---|
| Crizotinib (n = 11, 9) | 2167 ± 56 | 1489 ± 44 |
| PF-06260182 (n = 11, 9) | 634.3 ± 82 | 422.3 ± 55 |
Participants were evaluated for the effect of dacomitinib on steady-state PK of crizotinib. PK of crizotinib alone was evaluated on Day -1 (one day before C1D1 on which the combination treatment of crizotinib and dacomitinib started) after a lead in period of continuous BID dosing of crizotinib for approximately 12 days (±2 days). PK of crizotinib and dacomitinib in combination treatment was evaluated on Day 1 of Cycle 2. Blood samples for crizotinib full PK were to be collected on Day -1 and Day 1 of Cycle 2. The below table included PK data for Cmin. Cmin was observed directly from data.
| ng/mL | Crizotinib Alone (Expansion Cohort 1) | Crizotinib + Dacomitinib (Expansion Cohort 1) |
|---|---|---|
| Crizotinib (n = 16, 13) | 181.8 ± 64 | 102.8 ± 51 |
| PF-06260182 (n = 16, 13) | 47.22 ± 99 | 25.53 ± 60 |
Participants were evaluated for the effect of dacomitinib on steady-state PK of crizotinib. PK of crizotinib alone was evaluated on Day -1 (one day before C1D1 on which the combination treatment of crizotinib and dacomitinib started) after a lead in period of continuous BID dosing of crizotinib for approximately 12 days (±2 days). PK of crizotinib and dacomitinib in combination treatment was evaluated on Day 1 of Cycle 2. Blood samples for crizotinib full PK were to be collected on Day -1 and Day 1 of Cycle 2. The below table included PK data for Cmax. Cmax was observed directly from data.
| ng/mL | Crizotinib Alone (Expansion Cohort 1) | Crizotinib + Dacomitinib (Expansion Cohort 1) |
|---|---|---|
| Crizotinib (n = 16, 13) | 306.0 ± 57 | 191.5 ± 43 |
| PF-06260182 (n = 16, 13) | 82.92 ± 79 | 51.15 ± 56 |
Participants were evaluated for the effect of dacomitinib on steady-state PK of crizotinib. PK of crizotinib alone was evaluated on Day -1 (one day before C1D1 on which the combination treatment of crizotinib and dacomitinib started) after a lead in period of continuous BID dosing of crizotinib for approximately 12 days (±2 days). PK of crizotinib and dacomitinib in combination treatment was evaluated on Day 1 of Cycle 2. Blood samples for crizotinib full PK were to be collected on Day -1 and Day 1 of Cycle 2. The below table included PK data for Tlast. Tlast was observed directly from data.
| Hour | Crizotinib Alone (Expansion Cohort 1) | Crizotinib + Dacomitinib (Expansion Cohort 1) |
|---|---|---|
| Crizotinib (n = 16, 13) | 9.650 ± 57 | 9.000 ± 43 |
| PF-06260182 (n = 16, 13) | 9.650 ± 79 | 9.000 ± 56 |
Participants were evaluated for the effect of dacomitinib on steady-state PK of crizotinib. PK of crizotinib alone was evaluated on Day -1 (one day before C1D1 on which the combination treatment of crizotinib and dacomitinib started) after a lead in period of continuous BID dosing of crizotinib for approximately 12 days (±2 days). PK of crizotinib and dacomitinib in combination treatment was evaluated on Day 1 of Cycle 2. Blood samples for crizotinib full PK were to be collected on Day -1 and Day 1 of Cycle 2. The below table included PK data for Tmax. Tmax was observed directly from data as time of first occurrence.
| Hour | Crizotinib Alone (Expansion Cohort 1) | Crizotinib + Dacomitinib (Expansion Cohort 1) |
|---|---|---|
| Crizotinib (n = 16, 13) | 2.04 ± 57 | 3.20 ± 43 |
| PF-06260182 (n = 16, 13) | 3.96 ± 79 | 3.95 ± 56 |
PK samples for full PK evaluation of dacomitinib were drawn on Day -1 (one day before C1D1 on which the combination treatment of crizotinib and dacomitinib started) and on C2D1. Dacomitinib and PF-05199265 PK parameter (AUClast) following dacomitinib alone and in combination with crizotinib are summarized in the below table. AUClast was calculated using Linear/Log trapezoidal method.
| ng•hr/mL | Dacomitinib Alone (Expansion Cohort 2) | Crizotinib + Dacomitinib (Expansion Cohort 2) |
|---|---|---|
| Dacomitinib (n = 6, 5) | 1016 ± 45 | 1148 ± 44 |
| PF-05199265 (n = 7, 6) | 80.94 ± 598 | 78.22 ± 42 |
PK samples for full PK evaluation of dacomitinib were drawn on Day -1 (one day before C1D1 on which the combination treatment of crizotinib and dacomitinib started) and on C2D1. Dacomitinib and PF-05199265 PK parameter (AUC24) following dacomitinib alone and in combination with crizotinib are summarized in the below table. AUC24 was calculated using Linear/Log trapezoidal method.
| ng•hr/mL | Dacomitinib Alone (Expansion Cohort 2) | Crizotinib + Dacomitinib (Expansion Cohort 2) |
|---|---|---|
| Dacomitinib (n = 6, 5) | 995.7 ± 45 | 1148 ± 44 |
| PF-05199265 (n = 7, 6) | 78.57 ± 587 | 78.36 ± 42 |
PK samples for full PK evaluation of dacomitinib were drawn on Day -1 (one day before C1D1 on which the combination treatment of crizotinib and dacomitinib started) and on C2D1. Dacomitinib and PF-05199265 PK parameter (Cmin) following dacomitinib alone and in combination with crizotinib are summarized in the below table. Cmin was observed directly from data.
| ng/mL | Dacomitinib Alone (Expansion Cohort 2) | Crizotinib + Dacomitinib (Expansion Cohort 2) |
|---|---|---|
| Dacomitinib (n = 6, 5) | 33.11 ± 58 | 39.92 ± 47 |
| PF-05199265 (n = 7, 6) | 5.440 ± 83 | 2.901 ± 47 |
PK samples for full PK evaluation of dacomitinib were drawn on Day -1 (one day before C1D1 on which the combination treatment of crizotinib and dacomitinib started) and on C2D1. Dacomitinib and PF-05199265 PK parameter (Cmax) following dacomitinib alone and in combination with crizotinib are summarized in the below table. Cmax was observed directly from data.
| ng/mL | Dacomitinib Alone (Expansion Cohort 2) | Crizotinib + Dacomitinib (Expansion Cohort 2) |
|---|---|---|
| Dacomitinib (n = 6, 5) | 47.15 ± 44 | 59.58 ± 49 |
| PF-05199265 (n = 7, 6) | 4.222 ± 375 | 4.070 ± 37 |
PK samples for full PK evaluation of dacomitinib were drawn on Day -1 (one day before C1D1 on which the combination treatment of crizotinib and dacomitinib started) and on C2D1. Dacomitinib and PF-05199265 PK parameter (Tlast) following dacomitinib alone and in combination with crizotinib are summarized in the below table. Tlast was observed directly from data.
| Hour | Dacomitinib Alone (Expansion Cohort 2) | Crizotinib + Dacomitinib (Expansion Cohort 2) |
|---|---|---|
| Dacomitinib (n = 6, 5) | 24.40 ± 44 | 23.80 ± 49 |
| PF-05199265 (n = 7, 6) | 24.50 ± 375 | 23.80 ± 37 |
PK samples for full PK evaluation of dacomitinib were drawn on Day -1 (one day before C1D1 on which the combination treatment of crizotinib and dacomitinib started) and on C2D1. Dacomitinib and PF-05199265 PK parameter (Tmax) following dacomitinib alone and in combination with crizotinib are summarized in the below table. Tmax was observed directly from data as time of first occurrence.
| Hour | Dacomitinib Alone (Expansion Cohort 2) | Crizotinib + Dacomitinib (Expansion Cohort 2) |
|---|---|---|
| Dacomitinib (n = 6, 5) | 16.0 ± 44 | 5.92 ± 49 |
| PF-05199265 (n = 7, 6) | 5.90 ± 375 | 4.35 ± 37 |
Collected over Up to Maximum of treatment duration + 28 days for each participant (could be 295 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PF-02341066, 200 mg BID/ PF-00299804, 30 mg QD | — | 6/14 (42.9%) | 14/14 (100%) |
| PF-02341066, 200 mg BID/ PF-00299804, 45 mg QD | — | 2/6 (33.3%) | 6/6 (100%) |
| PF-02341066, 250 mg BID/ PF-00299804, 30 mg QD | — | 1/7 (14.3%) | 7/7 (100%) |
| PF-02341066, 250 mg QD/ PF-00299804, 45 mg QD | — | 4/6 (66.7%) | 6/6 (100%) |
| Expansion Cohort 1 | — | 9/25 (36%) | 25/25 (100%) |
| Expansion Cohort 2 | — | 9/12 (75%) | 12/12 (100%) |
| Event | PF-02341066, 200 mg BID/ PF-00299804, 30 mg QD | PF-02341066, 200 mg BID/ PF-00299804, 45 mg QD | PF-02341066, 250 mg BID/ PF-00299804, 30 mg QD | PF-02341066, 250 mg QD/ PF-00299804, 45 mg QD | Expansion Cohort 1 | Expansion Cohort 2 |
|---|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 0/14 | 0/6 | 0/7 | 1/6 | 0/25 | 0/12 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/14 | 0/6 | 0/7 | 1/6 | 0/25 | 0/12 |
| SyncopeCardiac disorders | 0/14 | 0/6 | 0/7 | 1/6 | 0/25 | 0/12 |
| DiarrhoeaGastrointestinal disorders | 0/14 | 0/6 | 0/7 | 0/6 | 2/25 | 2/12 |
| NauseaGastrointestinal disorders | 0/14 | 0/6 | 0/7 | 1/6 | 0/25 | 1/12 |
| Disease progressionGeneral disorders | 1/14 | 0/6 | 0/7 | 0/6 | 2/25 | 2/12 |
| HypersensitivityImmune system disorders | 0/14 | 1/6 | 0/7 | 0/6 | 0/25 | 0/12 |
| Blood creatinine increasedInvestigations | 0/14 | 0/6 | 0/7 | 1/6 | 0/25 | 0/12 |
| DehydrationMetabolism and nutrition disorders | 0/14 | 0/6 | 0/7 | 1/6 | 1/25 | 0/12 |
| HyperuricaemiaMetabolism and nutrition disorders | 1/14 | 0/6 | 0/7 | 1/6 | 0/25 | 0/12 |
| Event | PF-02341066, 200 mg BID/ PF-00299804, 30 mg QD | PF-02341066, 200 mg BID/ PF-00299804, 45 mg QD | PF-02341066, 250 mg BID/ PF-00299804, 30 mg QD | PF-02341066, 250 mg QD/ PF-00299804, 45 mg QD | Expansion Cohort 1 | Expansion Cohort 2 |
|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 12/14 | 6/6 | 6/7 | 6/6 | 19/25 | 10/12 |
| NauseaGastrointestinal disorders | 10/14 | 4/6 | 5/7 | 6/6 | 19/25 | 10/12 |
| VomitingGastrointestinal disorders | 9/14 | 2/6 | 1/7 | 5/6 | 11/25 | 6/12 |
| Decreased appetiteMetabolism and nutrition disorders | 7/14 | 4/6 | 3/7 | 3/6 | 10/25 | 5/12 |
| RashSkin and subcutaneous tissue disorders | 9/14 | 3/6 | 3/7 | 3/6 | 5/25 | 7/12 |
| FatigueGeneral disorders | 7/14 | 3/6 | 3/7 | 3/6 | 13/25 | 7/12 |
| ParonychiaInfections and infestations | 6/14 | 2/6 | 1/7 | 3/6 | 8/25 | 7/12 |
| Oedema peripheralGeneral disorders | 7/14 | 2/6 | 3/7 | 1/6 | 7/25 | 4/12 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 3/14 | 3/6 | 0/7 | 0/6 | 2/25 | 0/12 |
| Dermatitis acneiformSkin and subcutaneous tissue disorders | 4/14 | 1/6 | 1/7 | 3/6 | 10/25 | 2/12 |
| Age, Continuous(Years) | Crizotinib 200 mg BID/ Dacomitinib 30 mg QD | Crizotinib 200 mg BID/ Dacomitinib 45 mg QD | Crizotinib 250 mg BID/ Dacomitinib 30 mg QD | Crizotinib 250 mg QD/ Dacomitinib 45 mg QD | Expansion Cohort 1 | Expansion Cohort 2 | Total |
|---|---|---|---|---|---|---|---|
| Mean | 53.6 ± 9.87 | 61.7 ± 7.53 | 54.7 ± 11.34 | 62.2 ± 13.61 | 61.8 ± 10.83 | 59.6 ± 11.74 | 59.1 ± 11.05 |
| Sex: Female, Male(Participants) | Crizotinib 200 mg BID/ Dacomitinib 30 mg QD | Crizotinib 200 mg BID/ Dacomitinib 45 mg QD | Crizotinib 250 mg BID/ Dacomitinib 30 mg QD | Crizotinib 250 mg QD/ Dacomitinib 45 mg QD | Expansion Cohort 1 | Expansion Cohort 2 | Total |
|---|---|---|---|---|---|---|---|
| Female | 5 | 5 | 6 | 2 | 16 | 9 | 43 |
| Male | 9 | 1 | 1 | 4 | 9 | 3 | 27 |
The record gives a start of Aug 2010, a primary completion of Feb 2014 and a completion of Feb 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2015, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Crizotinib · Dacomitinib
Carcinoma, Non-Small-Cell Lung →